The International Parkinson and Movement Disorder Society (MDS) gathers thousands of clinicians, researchers, trainees, and industry supporters to discuss the diagnosis and treatment of movement disorders on an annual basis.
The Future of Parkinson Disease Treatment With Innovative Wearable Devices: Alistair Mackett, MD
September 24th 2023The movement disorder specialist at Cambridge University Hospitals NHS Foundation Trust discussed the rise of wearable technology for managing Parkinson disease to potentially empower patients and monitor the disease at early stages. [WATCH TIME: 4 minutes]
Neurobiological Insights Into Gait and Balance Control in Parkinson Disease
September 5th 2023Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.
Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity
September 4th 2023On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.
Levodopa as Initial Parkinson Treatment Shows Best Long-Term Prognostic Outcome for Quality of Life
September 1st 2023When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.
Machine Learning Algorithm Accurately Diagnoses Parkinsonian Syndromes, Study Shows
September 1st 2023Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.
Machine Learning Algorithm Shows Ability to Distinguish Tic From NonTic Movements
August 31st 2023Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.
NeuroVoices: Andrew Singleton, PhD, on Expanding the Genomic Pool for Parkinson Disease
August 30th 2023The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.
Machine Learning Approach Shows Strong Ability to Predict Gait Dysfunction in Parkinson Disease
August 29th 2023Previous neuroimaging studies in Parkinson disease suggest an altered interaction at a structural and functional level between cortical and subcortical areas of the brain that each contribute to gait dysfunction.
Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease
September 19th 2022One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.
Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder
September 17th 2022Danielle Kipnis, MA, of Columbia University, discussed key components of a yoga program for individuals with functional neurological disorder and from the evaluation, found it feasibility as an intervention.
NeuroVoices: David R. Lynch, MD, PhD, on the First Potentially Approved Friedreich Ataxia Treatment
September 29th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the state of care for Friedrich ataxia and omaveloxolone’s potential to become its first approved therapy.
Mechanistic Action and FDA Outlook for Omaveloxolone in Friedreich Ataxia: David R. Lynch, MD, PhD
September 27th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]
Developing Interventions to Address Mental Health in Parkinson Disease: Lisanne Dommershuijsen, MSc
September 26th 2021The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]
COVID-19 Stressors and Mental Health in Parkinson Disease: Lisanne Dommershuijsen, MSc
September 25th 2021The PhD candidate in the epidemiology department at Erasmus University Medical Center in the Netherlands discussed the need for tailored treatment in light of the COVID-19 pandemic. [WATCH TIME: 4 minutes]